Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14395129 | 0.92 | GRM5 (0.41) | GRM5ADORA1AHRADORA3TMIGD3 | |
| SCHEMBL11931151 | 0.91 | GRM5 (0.39) | GRM5ADORA1AHRADORA3TMIGD3 | |
| SCHEMBL11931149 | 0.90 | PARP1 (0.44) | GRM5ADORA1AHRADORA3TMIGD3 | |
| SCHEMBL11931150 | 0.85 | ADORA3 (0.52) | ADORA3TMIGD3ALDH1A1 | |
| SCHEMBL11931153 | 0.82 | ADORA3 (0.50) | ADORA3TMIGD3ALDH1A1 | |
| SCHEMBL11931155 | 0.82 | MAPT (0.41) | AHRALDH1A1 | |
| SCHEMBL11931156 | 0.77 | HPGD (0.38) | AHRALDH1A1 | |
| SCHEMBL14395117 | 0.72 | FAAH (0.38) | ALDH1A1 | |
| SCHEMBL11931152 | 0.72 | CDK2 (0.44) | AHRALDH1A1 | |
| SCHEMBL13998498 | 0.71 | GSK3B (0.48) | AHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942900-B1 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | MERCK SHARP & DOHME (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | GRM5 3594/4885ADORA1 4040/4885ATM 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.